Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G.
BMS-378806 targets virus entry by inhibiting the binding of HIV-1 gp120 to the CD4 receptor. Env sequences (n = 1226) of subtypes A-G were analysed to determine the frequency of mutations associated with resistance to BMS-378806. In line with reported sensitivity data, background genotypic resistance to BMS-378806 among non-B HIV-1 viruses was found to be higher than in subtype B. These data suggest that BMS-378806 may have reduced efficacy against non-B viruses.
Moore
Penny L
PL
AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa.
Cilliers
Tonie
T
Morris
Lynn
L
D024882:Drug Resistance, Viral; D005814:Genes, Viral / Q000235:genetics; D015752:Genes, env / Q000235:genetics; D005838:Genotype; D015497:HIV-1 / Q000235:genetics* / Q000302:isolation & purification; D009154:Mutation; D010879:Piperazines
C477855:BMS-378806; D010879:Piperazines